Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Allergan Rejects Valeant Pharmaceuticals Takeover bid

By BiotechDaily International staff writers
Posted on 18 May 2014
Allergan (Irvine, CA, USA), the manufacturer of Botox, has rejected a USD 46 billion unsolicited takeover bid made by Valeant Pharmaceuticals (Valeant; Laval, Canada), on the basis that the proposal substantially undervalues the company.

The Valeant offer was made in conjunction with Pershing Square Capital Management (New York, NY, USA), an activist hedge fund founded and run by Bill Ackman, which reached a 5% ownership stake in Allergan on April 10, 2014, and started aggressively buying more shares until reaching a 9.7% hold on the company. At that point, Valeant and Ackman made an unsolicited cash and stock offer for the company that represented a 32% premium on Allergan's market value at the time.

The offer was rejected by the Allergan board of directors unanimously, claiming that Valeant's plan for an (at least) USD 2.7 billion annual cost cut would prevent the company from delivering growth that it could produce on its own, and that the offer was too risky. Allergan said that the current level of research-and-development and sales-and-marketing spending had enabled Allergan to launch several new products in recent years, increasing annual sales by an average of 11% since 2011. The company set a target of a 20%–25% increase in earnings per share in 2015.

Allergan's rejection was expected, since the company has adopted the so-called “poison pill defense”, wherein if any unapproved investor acquires more than 10% of Allergan's shares, other stockholders would have the right to buy discounted shares. Valeant, on its part, said that it is planning to hold a special meeting of Allergan shareholders to remove some (or all) of the company's directors; it also said it may call a referendum to see if the shareholders support Allergan-Valeant negotiations. The rejection of the offer also potentially sets the stage for a proxy battle between the companies.

“Valeant's method of cutting and slashing doesn't hold up for more than a brief period of time,” said David Pyott, CEO of Allergan. “Given Valeant's aversion to early-stage investment, under Valeant's ownership, this franchise would not have yielded the growth and remarkable value that Allergan has achieved.”

“We are disappointed that Allergan has rejected our value-creating offer without engaging in any substantive discussions with Valeant or Allergan’s largest stockholder, Pershing Square,” Valeant said in a statement. “We remain committed to pursuing this transaction.”

Valeant has bought roughly a half-dozen companies in the last two years, including contact lens maker Bausch & Lomb for USD 8.7 billion in 2013, shortly after acquiring Medicis Pharmaceuticals for USD 2.6 billion at the end of 2012. Valeant has grown by cutting spending and buying companies or proven products that will boost earnings, and has set its sights on becoming one of the world's five biggest pharmaceutical companies.

Related Links:

Allergan
Valeant Pharmaceuticals



SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel

MicroRNA Panel Identifies Mild Brain Trauma in a Mouse Model

A study conducted on a mouse model found that a panel of 13 serum microRNAs (miRNAs) could be used to identify the severity of damage to the brain and the risk of developing adverse effects following mild traumatic brain injury (mTBI). MTBI is a heterogeneous injury that may lead to the development of neurological and... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: Mouse kidneys, liver, and pancreas imaged after treatment with a variety of protocols: a saline solution, Scale, SeeDB (see deep brain), CUBIC, and carotid body (CB) perfusion (which was used in this study) (Photo courtesy of RIKEN Quantitative Biology Center).

Nearly Transparent Mice Offers Potential of Whole-Organism Imaging

Japanese researchers have developed a method that combines tissue decolorization and light-sheet fluorescent microscopy to take extremely detailed images of the interior of individual organs and even entire... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.